Evolution of the Average Target: Valneva SE

Evolution of the Average Target - Valneva SE

Evolution of the Target Price: Valneva SE

Evolution of the Target Price - Valneva SE

Changes in Analyst Recommendations: Valneva SE

79b8d42cb9318c23481241a8340.-vo1_0dZrFy8spUpnsoH9k662kz5mU96tDlgWfUKc3g.kZxYzjM49mWExc9swY9RlT3crnm-4SxD7WMKK55vGzOisleuAnSVKdvbpQ~6855b98e39d61cc1f1f8acf53a82d388
08-11 TD Cowen Initiates Valneva at Buy Rating, With $12 Price Target MT
05-13 French Analyst Ratings: Aramis and Valneva penalized following profit warnings Zonebourse
04-30 Schneider Electric, Capgemini, Societe Generale... stocks to watch today in Paris Zonebourse
04-22 Goldman Sachs Downgrades Valneva to Sell From Neutral, Adjusts Price Target to $4.90 From $7.50 MT
04-22 French Analyst Ratings: Thales, Vallourec and Valneva in the Spotlight Zonebourse
03-18 Valneva heads for fourth consecutive gain following annual results Zonebourse
01-20 Stifel Reiterates Buy Rating and Price Target on Valneva Zonebourse
01-06 Valneva, Biggest Gainer on SBF 120 and SRD at Close of Tuesday, January 6, 2026 Zonebourse
01-06 Valneva Surges on Positive Broker Comments Zonebourse
01-06 CAC 40 Lags Behind; Valneva in Demand Zonebourse
01-06 Valneva Posts Strongest Midday Gain on SBF 120, Tuesday, January 6, 2026 Zonebourse
01-06 Stock of the Day in Paris – Valneva Bolstered by Stifel Zonebourse
01-06 Stifel Raises Price Target for Valneva Zonebourse
01-06 Analysts' calls of the day: Bernstein favors Thales over BAE Systems and Dassault Aviation Zonebourse
11-20 Stifel Reiterates Buy Recommendation on Valneva Zonebourse
11-04 Valneva SE Announces Positive Results of Its Phase 1 Clinical Trial Investigating the Safety and Immunogenicity of VLA1601 CI
03/09/25 Valneva publishes positive data for its Lyme disease vaccine candidate, stock rises RE
26/08/25 Valneva: Stifel Adjusts Price Target Following FDA Suspension of Ixchiq License Zonebourse
26/08/25 Valneva: Stifel adjusts target price Zonebourse
12/08/25 Valneva: Oddo BHF confirms 'outperform' rating Zonebourse
14/07/25 Valneva Shares Surge After EMA Lifts Restriction on Chikungunya Vaccine RE
13/08/24 Valneva: Oddo BHF confirms its recommendation on the stock Zonebourse
24/06/24 Valneva rises after Canadian approval for its chikungunya vaccine RE
05/02/24 Valneva: Oddo BHF confirms its recommendation on the stock Zonebourse
02/01/24 Valneva: Oddo BHF remains positive Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+141.44%
+13.99%
+24.38%
+19.43%
+29.48%
+11.87%
+19.5%
+46.79%
+0.6%
+21.55%
Average +32.90%
Weighted average by Cap. +20.43%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.565EUR
Average target price
6.193EUR
Spread / Average Target
+141.44%
High Price Target
12.00EUR
Spread / Highest target
+367.84%
Low Price Target
2.150EUR
Spread / Lowest Target
-16.18%

Analyst Consensus Detail

Analyst consensus - Valneva SE

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Valneva SE
Trader
Investor
Global
Quality
ESG MSCI
BBB
Ratings Surperformance© - Valneva SE
  1. Stock Market
  2. Stocks
  3. VLA Stock
  4. Consensus Valneva SE